AGTR1 and Alzheimer disease: A growing body of epidemiological and experimental evidence suggests a potential role of the brain RAS in the development and progression of AD, with its inhibition, through ACE inhibitors (ACEis) or AT1 receptor blockers (ARBs), reducing AD signs and symptoms [12].